Loans4Less.com, an online mortgage loan brokerage firm focused on conforming loans, today announced the company is ramping up its brand exposure and market penetration by launching a targeted newspaper advertising campaign to a circulation of more than 1.7 million readers in California.

It wasn’t that many years ago when solar power was hard to consider as a serious mainstream energy source, with what were then low-efficiency solar collectors and crude support technologies. Today, even though continuing technological breakthroughs and large scale installations have turned that impression around, there is still a sense that small remotely based solar PV systems are only good for powering low-consumption electronics, and that such systems are not yet ready to do any “heavy lifting.”

International Stem Cell Corp., a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells, announced today that $1 million has been invested by a number of existing long-standing investors through a private placement on the same terms as the transaction with management reported on January 22, 2013.

Read More : http://newswalls.blogspot.in/2013/03/like-all-sleight-of-hand-games-it.html

Spring is in the air, stock markets are driving higher than ever before, and happy days are here again.

Or are they?

Biotech small-cap Advaxis has been nominated for the Vaccine Industry Excellence (ViE) Award sponsored by Novartis Vaccines and Diagnostics. The ViE award recognizes companies and individuals that have demonstrated influential accomplishments and contributions to the vaccine industry within the prior 12 months.

Viscount Systems, a leading-edge, high technology supplier of security systems and software, today announced that it has received conditional funding of up to $150,000 from the National Research Council of Canada Industrial Research Assistance Program (IRAP).

IRAP support will be used to advance the development of Viscount’s Freedom access control platform and to expand system capabilities to a number of key areas, including mobile devices, preparing for U.S. Government full FICAM compliance, enhancing the Freedom Microsoft Active Directory platform, and enhanced encryption.

Advaxis, a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases, today announced that Dr. Nicola Mason, lead investigator of the Penn canine study, and Dr. Yvonne Paterson, scientific founder of Advaxis, have been given the inaugural University of Pennsylvania One Health Award for their research of Advaxis’ proprietary immunotherapy, ADXS-cHER2, for the treatment of canine osteosarcoma.